tourmalinebio.com - נכסים נקיים למניה בודדת TRML

The market price visualization for Tourmaline Bio, Inc. (TRML) demonstrates the quotes of a biotech firm developing therapies to combat autoimmune pathologies, aiming to capture the niche of rare rheumatological diseases. The current figure stands at 10.05, while the company lacks a stable cash flow and relies on venture capital investments. Growth potential is based on the test results of the TOUR006 antibody and strategic collaborations.

Investors view Tourmaline Bio, Inc. (TRML) as a promising biotech firm with high risk prior to commercialization. This metric determines the share of net assets per share after deducting all liabilities. The price action in the book value per share reflects the market consensus regarding the issuer's material stability. For Tourmaline Bio, Inc. (TRML), growth in this indicator serves as a defensive buffer, offsetting the lack of revenue during Phase 2 clinical trials. Accumulating capital on the balance sheet minimizes bankruptcy risk before the drug reaches the market.